Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 19Recurrence 5Sarcoma, Kaposi 2Neoplasms 2Acquired Immunodeficiency Syndrome 2Plasmacytoma 1Plasmablastic Lymphoma 1Neoplasms, Plasma Cell 1Multi-centric Castleman's Disease 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Epstein-Barr Virus Infections 1Burkitt Lymphoma 1

Interventions

Dexamethasone 2Bortezomib 2pomalidomide 1isatuximab 1fludarabine phosphate 1elotuzumab 1carfilzomib 1belantamab mafodotin 1Whole-Body Irradiation 1Tacrolimus 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Lenalidomide 1Etoposide 1Cyclosporine 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × pomalidomide × 30 days × Clear all
NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡